This review connects target discovery to clinical development by integrating spatial and longitudinal tumor biology with payload selection, delivery engineering, biomarker design, manufacturing, and mechanism-driven trials, and argues that the clinically actionable unit in diffuse glioma is often a target-anatomical compartment pair rather than a molecular target considered in isolation.
Abstract
Diffuse gliomas are increasingly defined by molecular alterations, yet the clinical translation of gene-targeted therapies remains constrained by a persistent mismatch between target biology and spatial pharmacology. In this review, we connect target discovery to clinical development by integrating spatial and longitudinal tumor biology with payload selection, delivery engineering, biomarker design, manufacturing, and mechanism-driven trials. Recent clinical practices in locoregional CAR-T cells, oncolytic and gene-delivery viruses, tumor-homing myeloid cell gene therapy, mutation- and neoantigen-directed vaccination, RNA nanomedicines, and emerging genome-editing strategies suggest that vehicle and route of administration dramatically change drug exposure, therapeutic index, immune activity, and resistance. We therefore propose the concept of “delivery-adjusted targetability,” in which a candidate target is judged not only by biological dependency but also by clonality, longitudinal stability, normal-brain expression, anatomical distribution, modality compatibility, and achievable target engagement. We further argue that the clinically actionable unit in diffuse glioma is often a target-anatomical compartment pair rather than a molecular target considered in isolation. Moreover, we advocate target-payload-vehicle-route-biomarker co-design and a stage-gated evidence package. This framework provides a potential way to compare otherwise dissimilar platforms, distinguish target failure from delivery failure, and reject biologically attractive but spatially implausible programs earlier. Treating molecular dependency and spatial access as a single design problem can make precision neuro-oncology more experimentally falsifiable and clinically actionable.
Glioblastoma (GBM) remains difficult to control. Monoclonal antibodies (mAbs) have transformed the treatment of several extracranial cancers, but they have not consistently improved survival in GBM. This narrative review examines the main biological and translational barriers to antibody-based therapy. It also evaluate...
Yang Zhou, You-Ming Li, Yu Chen et al.· Current Oncology· 0 citations
It is indicated that no single engineering strategy is sufficient to overcome the interconnected barriers of GBM, and future progress in GBM CAR therapy will therefore depend on combining complementary solutions rather than improving only one CAR feature.
Aleksandra Królikowska, Katarzyna Białkowska· International Immunopharmaco...· 0 citations
This review compares non-small cell lung cancer, pancreatic ductal adenocarcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma across four interconnected dimensions: resistance networks, tumor microenvironmental reprogramming, metastatic progression, and delivery-system design.
Na Zhao, Yang Zhang, Chao Qian et al.· Biochimica et biophysica act...· 0 citations
The major obstacles limiting CAR-T therapy in GBM are summarized and emerging strategies to overcome these challenges are discussed, paving the way for future CAR-T-based therapies in glioblastoma.
Lin Chen, Z. Zou· Critical reviews in oncology...· 0 citations
Radiotherapy‐triggered drug delivery systems (RDDS) promise to integrate the spatial precision of ionizing radiation with controllable pharmacological activation. However, clinical translation remains constrained by its reliance on supra‐clinical irradiation doses. Here, we present a unifying framework redefining RDDS...
Jianv Jiang, Tan-Feng Zhang, Junliang Dong et al.· Advancement of science· 1 citation
Oncolytic viruses (OVs) combine tumour-selective infection and replication with direct tumour-cell destruction and the capacity to induce antitumour immune responses. This review critically synthesises the cellular mechanisms, engineering strategies, preclinical development, clinical translation, major limitations, a...
N. Ng, Rebecca Shin-Yee Wong, Bey Hing Goh· Clinical and Experimental Me...· 0 citations
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 13, 2026
What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient. The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.
MIT News · Artificial Intelligence· news.mit.eduNov 12, 2026
MIT scientists developed a training method to generate models that simulate the effects of human activities on climate much more quickly than other approaches.